Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate

Figure 4

Percentage of patients with amenorrhoea at the end of each treatment interval with 5 mg of UPA (PP4; PEARL IV).